# Cochrane Library

# Trusted evidence.

# Informed decisions.

# Better health.

# Cochrane Database of Systematic Reviews

# NCT03582969 (Continued)

# Participants

# Inclusion criteria

- People ages 12–18 years with newly diagnosed (> 9 months) mild-to-moderate UC based on colonic biopsy and clinical disease activity (SCCAI 5–12)

# Exclusion criteria

- Severe, uncontrolled UC
- Use of immunosuppressive or anti-inflammatory medications (except mesalamine) at enrollment
- Active or uncontrolled bacterial, viral, or fungal infection requiring systemic therapy
- Delayed gastric emptying syndrome
- Known chronic aspiration
- History of significant allergy to foods not excluded from donor diet (excluded foods are tree nuts, peanuts, shellfish, eggs)
- Pregnancy or nursing
- Inability to swallow oral medications (pills)

# Interventions

# Experimental arm

- Oral capsules of healthy donor feces

# Control arm

- Oral placebo capsules

# Outcomes

# Primary outcome

- UC remission at 12 weeks (SCCAI < 3)

# Secondary outcomes

- Improvement in UC symptoms at 12 weeks (improvement in SCCAI)
- Laboratory markers of inflammation (CRP, WBC, ANC, stool calprotectin) at 12 weeks, and 6 and 12 months
- Improvement in UC endoscopic score based on Mayo score at 12 weeks, and 6 and 12 months
- Change in diversity and variability of gut microbiome at 12 weeks, and 6 and 12 months
- Use of UC treatments (glucocorticoids, immunosuppressives (e.g. azathioprine), or TNF antagonists) at 6 and 12 months
- Extraintestinal disease manifestations at 6 and 12 months

# Starting date

# Contact information

# Notes

# NCT03716388

# Study name

Fecal microbiota therapy vs 5-aminosalicylates for induction of remission in newly diagnosed mild-moderately active UC

# Methods

RCT conducted in India

# Participants

# Inclusion criteria

- Active UC

# Fecal transplantation for treatment of inflammatory bowel disease (Review)

Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.